19.48
+1.43(+7.92%)
Currency In USD
| Previous Close | 18.05 |
| Open | 18.26 |
| Day High | 19.9 |
| Day Low | 18.25 |
| 52-Week High | 53.08 |
| 52-Week Low | 16.61 |
| Volume | 361,932 |
| Average Volume | 849,779 |
| Market Cap | 1.34B |
| PE | -3.85 |
| EPS | -5.06 |
| Moving Average 50 Days | 20.52 |
| Moving Average 200 Days | 25.85 |
| Change | 1.43 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $1,213.71 as of February 05, 2025 at a share price of $19.48. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $367.06 as of February 05, 2025 at a share price of $19.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
GlobeNewswire Inc.
Feb 03, 2025 12:00 PM GMT
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
GlobeNewswire Inc.
Jan 10, 2025 12:00 PM GMT
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will combine vepdegestrant with a CDK4/6 inhibitor, also
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 10, 2024 2:05 PM GMT
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Safety and tolerability of the combinat